Viking’s Crash, Orforglipron’s Rise, Semaglutide CV Data, SlimBiome Deal & More
In this week’s Obesity Updates, we spotlight pivotal developments reshaping the global obesity treatment landscape—from emerging GLP-1 challengers and strategic product launches to regulatory milestones and major rebranding plays.
🔬 Key Highlights This Week:
📉 Viking Therapeutics’ shares plunge by nearly 43% after VK2735 obesity pill trial reveals moderate efficacy but high GI side effects
💊 Eli Lilly’s orforglipron impresses in Phase 3—nearly 60% of patients lost at least 10% body weight
🧬 Rhythm Pharma secures FDA Priority Review for setmelanotide targeting rare hypothalamic obesity—showing nearly 20% BMI reduction
❤️ Novo Nordisk set to present semaglutide cardiovascular data at ESC 2025—heart risk reduced by up to 26%
🤝 OptiBiotix inks new SlimBiome distribution deal with a leading weight management brand
🔄 ReShape Lifesciences rebrands as Medtimo under Biorad Medisys, aiming global expansion in obesity and neuro-rehab markets
Whether you’re in biotech, healthcare, or investment, these insights deliver an essential pulse on obesity innovation and strategy.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on obesity, weight loss therapies, and metabolic health
#ObesityUpdates #WeightLossDrugs #GLP1 #VK2735 #Orforglipron #Setmelanotide #Semaglutide #Wegovy #Ozempic #LucidQuest #ClinicalTrials #HealthcareStrategy #MetabolicHealth #SlimBiome #BiotechNews